AD							

Award Number: W81XWH-08-2-0075

TITLE: Prazosin for Treatment of Patients With PTSD and Comorbid Alcohol Dependence

PRINCIPAL INVESTIGATOR: Ismene Petrakis

CONTRACTING ORGANIZATION: Yale University

New Haven, CT 06520

REPORT DATE: July 2011

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command

Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release; distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

this burden to Department o 4302. Respondents should	f Defense, Washington Headqua be aware that notwithstanding ar	rters Services, Directorate for Info	rmation Operations and Reports (in shall be subject to any penalty f	0704-0188), 1215 Jeffer	ection of information, including suggestions for reducing son Davis Highway, Suite 1204, Arlington, VA 22202- a collection of information if it does not display a currently
1. REPORT DATE (L 01-07-2011	DD-MM-YYYY)	DR FORM TO THE ABOVE ADD 2. REPORT TYPE Annual	RESS.		ATES COVERED (From - To) IL 2010-30 JUN 2011
4. TITLE AND SUBT		7 1111001			CONTRACT NUMBER
Prazosin for Treat	ment of Patients Wi	th PTSD and Comor	bid Alcohol Dependo	5b. 0 W81	GRANT NUMBER 1XWH-08-2-0075 PROGRAM ELEMENT NUMBER
				3C. F	ROGRAW ELEMENT NOWIDER
6. AUTHOR(S)				5d. F	PROJECT NUMBER
Ismene Petrakis					
				5e. 1	ASK NUMBER
E-Mail: Ismene.F	Petrakis@yale.edu			5f. W	ORK UNIT NUMBER
7. PERFORMING OF	RGANIZATION NAME(S	AND ADDRESS(ES)			ERFORMING ORGANIZATION REPORT
Yale University				N	JMBER
New Haven, CT	06520				
U.S. Army Medic	al Research and Ma	NAME(S) AND ADDRES ateriel Command	S(ES)	10. 8	SPONSOR/MONITOR'S ACRONYM(S)
Fort Detrick, Mar	yland 21702-5012			44.6	SPONSOR/MONITOR'S REPORT
					NUMBER(S)
Approved for Pub	AVAILABILITY STATE				
13. SUPPLEMENTA	RYNOTES				
14. ABSTRACT					
Abstract on next	page.				
15. SUBJECT TERM	S				
Subject terms on	next page.				
16. SECURITY CLAS	SSIFICATION OF:		17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT	b. ABSTRACT	c. THIS PAGE		6	19b. TELEPHONE NUMBER (include area
U	U	U	UU	6	code)

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the

REPORT DOCUMENTATION PAGE

Form Approved

OMB No. 0704-0188

14. ABSTRACT Background: There is a high rate of comorbidity with alcohol dependence (AD) and post traumatic stress disorder (PTSD). The rates of TSD among individuals with AD are at least twice as high as those in the general population. In addition, alcohol dependence is the most lommon comorbid condition in men with PTSD. Despite this, little is known about how to best treat individuals with comorbid AD and TSD. The use of an alpha-1 adrenergic receptor antagonist represents a novel approach to treatment that may target symptoms of both AD nd PTSD. There is evidence of common neurobiological mechanisms that underlie both AD and PTSD. Prazosin is an alpha-1 adrenergic eceptor antagonist that has been used successfully in the treatment of trauma nightmares and sleep disturbance in combat veterans with TSD, and alcohol dependence. Dbjective: The objective of this study is to evaluate the efficacy of prazosis (16mg) versus placebo in reducing alcohol consumption and lecreasing symptoms of PTSD in patients with comorbid AD and PTSD. Methods: One hundred and twenty participants with a current liagnosis of AD and PTSD will be enrolled in a 13-week trial. They will be assigned, in a double-blind fashion, to either prazosin or placebo. findings: No findings are yet available for this study. Significance: This project will be the first to compare prazosin to placebo as effective reatments for reducing alcohol consumption and PTSD symptoms in patients with both AD and PTSD.

15. SUBJECT TERMS PTSD, alcohol dependence, treatment, Prazosin


THE MARKET OF PERPONEIRIE DEDCOM

Table of Contents

	Page
Introduction	3
Body	3
Key Research Accomplishments	4
Reportable Outcomes	4
Conclusion	4
References	4
Appendices	4

INTRODUCTION: The objective of this research is to evaluate the efficacy of Prazosin 16mg versus placebo in reducing alcohol consumption and decreasing symptoms of PTSD in patients with comorbid AD and PTSD. We hypothesize that Prazosin will significantly reduce the number of drinking days and reduce the symptoms of PTSD compared to placebo in patients with AD and PTSD. This is a double-blind, multi-site, randomized, 13-week, treatment trial. The recruitment for this study is planned for 4 years.

BODY: This report covers the period of the third year of funding. Our goals for the third year were to: continue subject recruitment, develop and implement new avenue for recruitment, create new liaisons for recruitment, and follow patients already recruited in the study. The goals for this year have been accomplished regarding continuous recruitment as well as initiation and implementation of new recruitment strategies. However, our goal to recruit a total of 83 subjects has not been reached. Below we provide graphical representation of our recruitment to date in relationship to the goals we outlined in our statement of work. Our recruitment is progressing, and we have developed and implemented a number of strategies to increase recruitment in the second year. At the West Haven site, we have allocated resources for newspaper advertisement, and we created new liaisons in the community. Our recruitment has improved but in order to reach our recruitment goal we need to recruit more subjects into the study.



Included in this report is a table that outlines our recruitment success – at both sites - to date.

Site	# Ss that have signed consent	# Ss enrolled	Ratio of Ss to target		
West Haven	69	25	25/72		
Bedford	44	26	26/48		

KEY RESEARCH ACCOMPLISHMENTS: This study is ongoing and the sample size is not large enough for statistical analysis of the data at this time.

REPORTABLE OUTCOMES: The PI gave a presentation at the American Psychiatric Association Annual meeting on the comorbidity of PTSD and alcohol dependence in 2009. An abstract was also submitted for the Military Health Research Forum. A poster was presented at the Research Society of Alcoholism meeting in Atlanta, GA (June, 2011) comparing demographic characteristics of patients with dual diagnosis of AD and PTSD and patients with only AD diagnosis.

CONCLUSION: To date, our sample size does not permit statistical analysis of the data. We can only report that to date, medication has been well tolerated. For this reporting period there was one report of a serious adverse event at Bedford – death of a participant. AE reports were submitted to VA and Yale IRBs and a report was also sent to the DOD. At this time the autopsy report is pending and the event has been deemed unrelated to study participation.

REFERENCES: None, to date.

APPENDICES: None, to date.